Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7746771 | 0.74 | DPP4 (0.36) | DPP4 | |
| SCHEMBL7748097 | 0.72 | DPP4 (0.36) | DPP4 | |
| SCHEMBL7747179 | 0.72 | DPP4 (0.36) | DPP4 | |
| SCHEMBL7742436 | 0.72 | DPP4 (0.36) | DPP4 | |
| SCHEMBL7749590 | 0.72 | DPP4 (0.37) | DPP4 | |
| SCHEMBL7750329 | 0.69 | L3MBTL1 (0.35) | DPP4 | |
| SCHEMBL7746660 | 0.69 | L3MBTL1 (0.35) | DPP4 | |
| SCHEMBL1734839 | 0.68 | DPP4 (0.36) | DPP4 | |
| SCHEMBL9866976 | 0.68 | ATM (0.42) | — | |
| SCHEMBL7749696 | 0.66 | DPP4 (0.36) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598312-B2 | Inhibitors of antigen presentation by MHC class II molecules | PROVID PHARMACEUTICALS, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20120252734-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | OLSON GARY LEE (US) | 2012-10-04 | — | — | US | disclosed |
| US-8222215-B2 | Methods for the use of inhibitors of antigen presentation by MHC class II molecules | PROVID PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| EP-1605963-B1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF | PROVID PHARMACEUTICALS INC (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110217324-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF | PROVID PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
| US-20090111755-A1 | METHODS FOR THE USE OF INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | PROVID PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
| US-7439231-B2 | Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof | PROVID PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-20040162242-A1 | Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof | NJEDA | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162242-A1 | Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof | HLA-DRB1, CD74, MICA | DPP4 670/4885 |
| US-20110217324-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF | HLA-DRB1, CD74, MICA | DPP4 1065/4885 |
| US-20090111755-A1 | METHODS FOR THE USE OF INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | HLA-DRB1, CD74, MICA | DPP4 990/4885 |
| US-20120252734-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | HLA-DRB1, CD74, MICA | DPP4 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.